Neuronetics, Inc. (STIM)

Market Cap	107.17M -62.1%
Revenue (ttm)	151.64M +69.5%
Net Income	-37.11M
EPS	-0.55
Shares Out	69.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,599,104
Open	1.550
Previous Close	1.540
Day's Range	1.460 - 1.590
52-Week Range	0.800 - 4.850
Beta	1.13
Analysts	Buy
Price Target	4.33 (+181.17%)
Earnings Date	May 5, 2026

About STIM

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 28, 2018
• Employees: 658
• Stock Exchange: NASDAQ
• Ticker Symbol: STIM
• Website: https://neurostar.com/neuronetics

Financial Performance

In 2025, Neuronetics's revenue was $149.16 million, an increase of 99.17% compared to the previous year's $74.89 million. Losses were -$39.00 million, -10.78% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for STIM stock is "Buy." The 12-month stock price target is $4.33, which is an increase of 181.17% from the latest price.

Price Target

$4.33

(181.17% upside)

Analyst Consensus: Buy